384 related articles for article (PubMed ID: 31617128)
1. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
2. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
Shimon I
Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
[TBL] [Abstract][Full Text] [Related]
3. Prolactinomas in males: any differences?
Duskin-Bitan H; Shimon I
Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists.
Tang H; Cheng Y; Huang J; Li J; Zhang B; Wu ZB
Front Endocrinol (Lausanne); 2021; 12():616339. PubMed ID: 33776913
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Prolactinoma.
Inder WJ; Jang C
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013562
[TBL] [Abstract][Full Text] [Related]
7. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.
Coopmans EC; van Meyel SWF; Pieterman KJ; van Ipenburg JA; Hofland LJ; Donga E; Daly AF; Beckers A; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2019 Aug; 181(2):K21-K27. PubMed ID: 31167168
[TBL] [Abstract][Full Text] [Related]
8. Management of Dopamine Agonist-Resistant Prolactinoma.
Maiter D
Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Almalki MH; Aljoaib NN; Alotaibi MJ; Aldabas BS; Wahedi TS; Ahmad MM; Alshahrani F
Hormones (Athens); 2017 Apr; 16(2):139-149. PubMed ID: 28742502
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonist-resistant prolactinomas.
Oh MC; Aghi MK
J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
[TBL] [Abstract][Full Text] [Related]
11. Refractory lactotroph adenomas.
Urwyler SA; Karavitaki N
Pituitary; 2023 Jun; 26(3):273-277. PubMed ID: 36928728
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide in the management of dopamine agonist-resistant prolactinomas.
Whitelaw BC; Dworakowska D; Thomas NW; Barazi S; Riordan-Eva P; King AP; Hampton T; Landau DB; Lipscomb D; Buchanan CR; Gilbert JA; Aylwin SJ
Clin Endocrinol (Oxf); 2012 Jun; 76(6):877-86. PubMed ID: 22372583
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
14. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C
Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548
[TBL] [Abstract][Full Text] [Related]
15. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
16. Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Souteiro P; Karavitaki N
Pituitary; 2020 Feb; 23(1):27-37. PubMed ID: 31522358
[TBL] [Abstract][Full Text] [Related]
17. Pasireotide: A potential therapeutic alternative for resistant prolactinoma.
Lasolle H; Vasiljevic A; Borson-Chazot F; Raverot G
Ann Endocrinol (Paris); 2019 Apr; 80(2):84-88. PubMed ID: 30318256
[TBL] [Abstract][Full Text] [Related]
18. The treatment of aggressive prolactinomas with everolimus.
Lin AL; Geer EB; Lala N; Page-Wilson G; Magge R; Young RJ; Tabar V
Pituitary; 2023 Aug; 26(4):474-481. PubMed ID: 37428396
[TBL] [Abstract][Full Text] [Related]
19. Management of resistant prolactinomas.
Olafsdottir A; Schlechte J
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
[TBL] [Abstract][Full Text] [Related]
20. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S
Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]